arrow
C

Claudia Proto

Fondazione IRCCS Istituto Nazionale dei Tumori
H指数:31
被引数:4,031

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Chronobiological Prognostic Model for Resected Stage I Non-Small-Cell Lung Cancer

基于昼夜节律的预后模型用于切除的I期非小细胞肺癌

Cancers
IF4.4
2026-10-050
OA
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC

可解释AI决策支持工具的临床可用性及非小细胞肺癌中多模态模型的评估

2026-09-130
OAAI
Leave No Data Behind: Exploring a new paradigm in oncology with foundation models and large language models

不留数据:探索基于基础模型和大型语言模型的肿瘤学新范式

2026-08-040
OAAI
A plain language summary of the SAVANNAH study: savolitinib plus osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification whose cancer had grown or spread on osimertinib

SAVANNAH研究的大众语言摘要:色瑞替尼联合奥希替尼用于EGFR突变型晚期非小细胞肺癌患者,这些患者的肿瘤在奥希替尼治疗后出现MET过表达和/或扩增,且肿瘤已进展或扩散。

2026-07-160
OA
Network analysis predicts pembrolizumab response in advanced NSCLC with PD-L1 < 50%

网络分析预测PD-L1<50%的晚期NSCLC对pembrolizumab的应答

2026-03-260
OA
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide tyme database

诱导治疗后的治疗反应:来自意大利全国性tyme数据库的晚期胸腺肿瘤结果

2025-12-050
PRE
Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group
2025-04-010
PRE
Unleashing precision: A review of targeted approaches in pleural mesothelioma (vol 203C, 104481, 2024)
2024-12-010
PRE
Unleashing precision: A review of targeted approaches in pleural mesothelioma
2024-11-012
OAAI
Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study

卡博替尼联合阿特珠单抗或单用卡博替尼治疗先前接受免疫检查点抑制剂治疗的晚期NSCLC患者: 1b COSMIC-021期研究的结果

2024-10-011
OA
Efficacy and safety of ramucirumab plus carboplatin and paclitaxel in untreated metastatic thymic carcinoma: RELEVENT phase II trial (NCT03921671)

ramucirumab联合卡铂和紫杉醇治疗未治疗的转移性胸腺癌的疗效和安全性: RELEVENT II期试验 (NCT03921671)

2024-09-012
OA
Digital pathology predicts PD-L1 expression in metastatic NSCLC patients treated with immunotherapy

数字病理学预测接受免疫治疗的转移性非小细胞肺癌患者的PD-L1表达

2024-09-010
PRE
Management of patients with extensive small-cell lung cancer in the immunotherapy era: An Italian consensus through a Delphi approach

免疫治疗时代广泛小细胞肺癌患者的管理: 通过Delphi方法达成的意大利共识

2024-07-011
PRE
Activity of osimeRTInib in non-small-cell lung Cancer with UNcommon epidermal growth factor receptor mutations: retrospective Observational multicenter study (ARTICUNO)

奥希替尼在具有罕见表皮生长因子受体突变的非小细胞肺癌中的活性: 回顾性观察性多中心研究 (ARTICUNO)

2024-06-011
OAAI
Dissecting circulating tumor cells phenotype in a cohort of locally advanced non-small cell lung cancer patients undergoing neoadjuvant chemotherapy
2024-03-220
PRE
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2024-03-011
OAAI
Artificial intelligence for predictive biomarker discovery in immuno-oncology: a systematic review

免疫肿瘤学中预测生物标志物发现的人工智能: 系统综述

2024-01-0138
OAAI
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non-Small-Cell Lung Cancer With Novel Driver Alterations
2023-11-011
OAAI